Recent testing seems to reveal that using the HPV vaccine (Gardasil) in young women ages 24-40, who show no signs of HPV, may have a significant protective effect. Since this group is at high risk for HPV (considered a risk for cervical cancer) exposure, this new application to safeguard a significant part of the female population from contracting HPV. The caveat is that you have to be tested to make sure that the cost of the vaccine is warranted, since many women in this age group may have already contracted HPV. If you have HPV, the vaccine offers no benefits.
Many women fail to realize that bio-identical hormones are not regulated by the FDA. The testing done to determine your bio-identical hormone needs is not standardized. And the bio-identical hormones have their own benefits and risks - this is not an innocuous treatment. Purity and inconsistency of doses is also a significant problem in this industry, and this can offer additional risk to patients.
0 comments:
Post a Comment